These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 31097097)

  • 21. Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.
    Williams CD; Allo MA; Gu L; Vashistha V; Press A; Kelley M
    PLoS One; 2023; 18(2):e0282020. PubMed ID: 36809528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations.
    Brambilla M; Beninato T; Piemontese A; Mazzeo L; Pircher CC; Manglaviti S; Ambrosini P; Signorelli D; Lorenzini D; Prelaj A; Ferrara R; Proto C; Lo Russo G; Pizzutilo EG; Ganzinelli M; Grande I; Capone I; Di Mauro RM; Conca E; Dumitrascu AD; Zanella C; Leporati R; Rota S; Garassino MC; Marchetti P; de Braud FM; Occhipinti M
    Clin Lung Cancer; 2023 Nov; 24(7):631-640.e2. PubMed ID: 37775370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy.
    Bilen MA; Shabto JM; Martini DJ; Liu Y; Lewis C; Collins H; Akce M; Kissick H; Carthon BC; Shaib WL; Alese OB; Steuer CE; Wu C; Lawson DH; Kudchadkar R; Master VA; El-Rayes B; Ramalingam SS; Owonikoko TK; Harvey RD
    BMC Cancer; 2019 Aug; 19(1):857. PubMed ID: 31464611
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer.
    Jiang T; Liu H; Qiao M; Li X; Zhao C; Su C; Ren S; Zhou C
    Clin Lung Cancer; 2018 Mar; 19(2):e177-e184. PubMed ID: 29175386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies.
    Marur S; Singh H; Mishra-Kalyani P; Larkins E; Keegan P; Sridhara R; Blumenthal GM; Pazdur R
    Semin Oncol; 2018 Aug; 45(4):220-225. PubMed ID: 30391014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.
    Suzuki H; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Kawase I
    Asia Pac J Clin Oncol; 2015 Jun; 11(2):121-8. PubMed ID: 24811212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma.
    Ishiyama Y; Kondo T; Nemoto Y; Kobari Y; Ishihara H; Tachibana H; Yoshida K; Hashimoto Y; Takagi T; Iizuka J; Tanabe K
    Urol Oncol; 2021 Dec; 39(12):834.e21-834.e28. PubMed ID: 34284929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small-Cell Lung Cancer Patients Treated in the Community Practice Setting.
    Nadler E; Espirito JL; Pavilack M; Boyd M; Vergara-Silva A; Fernandes A
    Clin Lung Cancer; 2018 Jul; 19(4):360-370. PubMed ID: 29576407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.
    Cortellini A; Ricciuti B; Facchinetti F; Alessi JVM; Venkatraman D; Dall'Olio FG; Cravero P; Vaz VR; Ottaviani D; Majem M; Piedra A; Sullivan I; Lee KA; Lamberti G; Hussain N; Clark J; Bolina A; Barba A; Benitez JC; Gorría T; Mezquita L; Hoton D; Aboubakar Nana F; Besse B; Awad MM; Pinato DJ
    Ann Oncol; 2021 Nov; 32(11):1391-1399. PubMed ID: 34400292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ERCC1 expression in circulating tumor cells (CTCs) using a novel detection platform correlates with progression-free survival (PFS) in patients with metastatic non-small-cell lung cancer (NSCLC) receiving platinum chemotherapy.
    Das M; Riess JW; Frankel P; Schwartz E; Bennis R; Hsieh HB; Liu X; Ly JC; Zhou L; Nieva JJ; Wakelee HA; Bruce RH
    Lung Cancer; 2012 Aug; 77(2):421-6. PubMed ID: 22555222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice.
    Faehling M; Kopp M; Schwenk B; Fallscheer S; Kramberg S; Eckert R
    Oncology; 2019; 97(4):228-235. PubMed ID: 31216560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer.
    Sekine K; Kanda S; Goto Y; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Ohe Y
    Lung Cancer; 2018 Oct; 124():179-188. PubMed ID: 30268458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG
    J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
    Cadranel J; Park K; Arrieta O; Pless M; Bendaly E; Patel D; Sasane M; Nosal A; Swallow E; Galebach P; Kageleiry A; Stein K; Degun R; Zhang J
    Lung Cancer; 2016 Aug; 98():9-14. PubMed ID: 27393500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma.
    Corrigan KL; Xu T; Sasaki Y; Lin R; Chen AB; Welsh JW; Lin SH; Chang JY; Ning MS; Gandhi S; O'Reilly MS; Gay CM; Altan M; Lu C; Cascone T; Koutroumpakis E; Sheshadri A; Zhang X; Liao L; Zhu XR; Heymach JV; Nguyen QN; Liao Z
    Radiother Oncol; 2024 Apr; 193():110121. PubMed ID: 38311031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibiotics are associated with worse outcomes in lung cancer patients treated with chemotherapy and immunotherapy.
    Elkrief A; Méndez-Salazar EO; Maillou J; Vanderbilt CM; Gogia P; Desilets A; Messaoudene M; Kelly D; Ladanyi M; Hellmann MD; Zitvogel L; Rudin CM; Routy B; Derosa L; Schoenfeld AJ
    NPJ Precis Oncol; 2024 Jul; 8(1):143. PubMed ID: 39014160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer.
    Bergqvist M; Holgersson G; Bondarenko I; Grechanaya E; Maximovich A; Andor G; Klockare M; Thureson M; Jerling M; Harmenberg J
    Acta Oncol; 2017 Mar; 56(3):441-447. PubMed ID: 27882820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.
    Rossi A; Di Maio M; Chiodini P; Rudd RM; Okamoto H; Skarlos DV; Früh M; Qian W; Tamura T; Samantas E; Shibata T; Perrone F; Gallo C; Gridelli C; Martelli O; Lee SM
    J Clin Oncol; 2012 May; 30(14):1692-8. PubMed ID: 22473169
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
    Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
    Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.